Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Agomelatine is the active ingredient of these drugs:
Austria Ireland Lithuania Poland
Austria Brazil Cyprus Finland France
Agomelatine is also found within below combination drugs:
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):